Emerging Biosimilars in Therapeutics

A biosimilar medicine is developed to be highly similar to a biological medicine that is already approved and available for patients, once the original patent has expired.

It is predicted that as patents expire over the next five years for a number of biological medicines with high sales, the development of biosimilar medicines for the treatment of cancer, diabetes, rheumatoid arthritis and multiple sclerosis will be seen. It is also predicted that the monoclonal antibodies (mABs) will comprise a large proportion of the biosimilars market along with biosimilar insulins, which are also expected to enter the insulin landscape in the coming years as the patents for major insulin products begin to expire. The proportion of different biosimilars that reached market are Low Molecular Weight Heparins 44%, Epoetins 19%, HGH 11%, G-CSFs 7%, Interferons 6%, Insulins 5%, Others 8%.

Biological medicines have revolutionised the treatment of a number of diseases that were previously untreatable. However, access for patients globally can be limited or difficult due to high costs, including development, materials and manufacturing costs which are much higher than traditional chemical medicines.3 The availability of biosimilar medicines could promote competition and bring down the price of biological medicines for the payer, and deliver cost savings.3 This means that patients may be able to access medicines which are lifesaving but may have previously been unaffordable both to health systems and patients

  • Biosimilars in Cancer therapeutics
  • Biosimilar Interleukins
  • Biosimilar Epoetins
  • Biosimilar TNF-α
  • Biosimilars in Fertility Treatment
  • Recombinant blood products
  • Biosimilar monoclonal antibodies
  • Recombinant therapeutic proteins
  • Biosimilar peptides
  • Insulin Biosimilars
  • Growth hormones
  • Recombinant vaccines
  • Biosimilars in rheumatology
  • Biosimilars interferon

Related Conference of Emerging Biosimilars in Therapeutics

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Emerging Biosimilars in Therapeutics Conference Speakers

Recommended Sessions

Related Journals

Are you interested in